- Home
- NOM vs RNTX Comparison
NOM vs RNTX Comparison
Compare NOM & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- RNTX
- Stock Information
- Founded
- NOM 1993
- RNTX 2001
- Country
- NOM United States
- RNTX United States
- Employees
- NOM N/A
- RNTX N/A
- Industry
- NOM Investment Managers
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- RNTX Health Care
- Exchange
- NOM Nasdaq
- RNTX Nasdaq
- Market Cap
- NOM 25.8M
- RNTX 28.0M
- IPO Year
- NOM N/A
- RNTX N/A
- Fundamental
- Price
- NOM $11.22
- RNTX $1.12
- Analyst Decision
- NOM
- RNTX Hold
- Analyst Count
- NOM 0
- RNTX 1
- Target Price
- NOM N/A
- RNTX N/A
- AVG Volume (30 Days)
- NOM 6.9K
- RNTX 128.0K
- Earning Date
- NOM 01-01-0001
- RNTX 11-13-2025
- Dividend Yield
- NOM 3.39%
- RNTX N/A
- EPS Growth
- NOM N/A
- RNTX N/A
- EPS
- NOM N/A
- RNTX N/A
- Revenue
- NOM N/A
- RNTX N/A
- Revenue This Year
- NOM N/A
- RNTX N/A
- Revenue Next Year
- NOM N/A
- RNTX N/A
- P/E Ratio
- NOM N/A
- RNTX N/A
- Revenue Growth
- NOM N/A
- RNTX N/A
- 52 Week Low
- NOM $8.52
- RNTX $1.04
- 52 Week High
- NOM $10.48
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- NOM 60.17
- RNTX 43.50
- Support Level
- NOM $10.84
- RNTX $1.07
- Resistance Level
- NOM $11.26
- RNTX $1.23
- Average True Range (ATR)
- NOM 0.19
- RNTX 0.12
- MACD
- NOM 0.03
- RNTX -0.01
- Stochastic Oscillator
- NOM 84.99
- RNTX 13.03
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.